Tower Research Capital LLC TRC Sells 2,391 Shares of Allergan PLC. (AGN)
Tower Research Capital LLC TRC lowered its stake in Allergan PLC. (NYSE:AGN) by 69.2% during the first quarter, Holdings Channel reports. The firm owned 1,062 shares of the company’s stock after selling 2,391 shares during the period. Tower Research Capital LLC TRC’s holdings in Allergan PLC. were worth $253,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the company. Graybill Bartz & Assoc Ltd. increased its position in Allergan PLC. by 1.5% in the first quarter. Graybill Bartz & Assoc Ltd. now owns 17,635 shares of the company’s stock worth $4,213,000 after buying an additional 255 shares during the last quarter. Cribstone Capital Management LLC increased its position in Allergan PLC. by 3.6% in the first quarter. Cribstone Capital Management LLC now owns 6,803 shares of the company’s stock worth $1,625,000 after buying an additional 236 shares during the last quarter. Atria Investments LLC increased its position in Allergan PLC. by 35.1% in the first quarter. Atria Investments LLC now owns 7,310 shares of the company’s stock worth $1,747,000 after buying an additional 1,900 shares during the last quarter. American National Bank increased its position in Allergan PLC. by 0.6% in the first quarter. American National Bank now owns 15,233 shares of the company’s stock worth $3,640,000 after buying an additional 95 shares during the last quarter. Finally, BKD Wealth Advisors LLC acquired a new position in Allergan PLC. during the first quarter worth approximately $219,000. Institutional investors own 84.77% of the company’s stock.
Allergan PLC. (AGN) traded up 0.57% during mid-day trading on Wednesday, hitting $241.10. The stock had a trading volume of 955,373 shares. The company has a 50-day moving average of $246.48 and a 200-day moving average of $237.35. The stock has a market cap of $80.98 billion, a price-to-earnings ratio of 7.51 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.
Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.35 earnings per share. On average, analysts anticipate that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.17%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
AGN has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective on the stock in a report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a report on Wednesday, May 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Royal Bank Of Canada set a $279.00 price objective on Allergan PLC. and gave the company a “buy” rating in a report on Wednesday, April 12th. Finally, Citigroup Inc. increased their price objective on Allergan PLC. to $261.00 and gave the company a “buy” rating in a report on Monday, April 24th. Eight analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Allergan PLC. presently has a consensus rating of “Buy” and a consensus price target of $274.24.
In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.36% of the stock is currently owned by corporate insiders.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.